Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

88 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-01

Study Completion Date

2021-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to better understand vitamin D catabolism and how it is affected by CKD and race.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetic Comparison of Vitamin's D2 and D3 in Stage 5 Chronic Kidney Disease Patients on Chronic Hemodialysis

NCT01675557

Chronic Kidney Disease

COMPLETED PHASE4

Impact of Vitamin D Therapies on Chronic Kidney Disease

NCT01222234

Chronic Kidney Disease (CKD) End-stage Renal Disease (ESRD)

COMPLETED NA

Vitamin D Supplement Study for Stage Three and Four Chronic Kidney Disease (CKD) Patients

NCT01173848

Chronic Kidney Disease Stage 3 and 4

TERMINATED PHASE3

Vitamin D Repletion in Chronic Kidney Disease

NCT00772772

Chronic Kidney Disease

COMPLETED EARLY_PHASE1

Impact of Vitamin D on Endothelial Function and Blood Biomarkers Including CD28 Null Cells in CKD

NCT02005718

CKd Patients With Stage 3 and 4

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Specifically, the study team will evaluate the metabolic clearance of 25-hydroxyvitamin D3 in individuals with varying degrees of CKD and among participants who self-report race as Caucasian, African American or African. The long-term goal of this work is to enhance the clinical evaluation and treatment of impaired vitamin D metabolism.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study Population

D6-25-hydroxyvitamin D3

Group Type EXPERIMENTAL

D6-25-hydroxyvitamin D3

Intervention Type DRUG

Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

D6-25-hydroxyvitamin D3

Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

stable isotope deuterium-labeled 25(OH)D3

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years
* Self-reported race Caucasian, African American, or African
* Serum total 25(OH)D 10-50 ng/mL
* Estimated GFR:

* 60 mL/min/1.73m2 (N=40) 15-45 mL/min/1.73m2 (N=40) \<15 mL/min/1.73m2, treated with hemodialysis (N=40)

Exclusion Criteria

* Primary hyperparathyroidism
* Gastric bypass
* Tuberculosis or sarcoidosis
* Current pregnancy
* Child-Pugh Class B or C cirrhosis (i.e. cirrhosis with ascites, hepatic encephalopathy, bilirubin \>=2 mg/dL, serum albumin \<=3.5 g/dL, or PT \>= 4 seconds)
* Use of vitamin D3, or vitamin D2 supplements exceeding a mean daily dose of 400 IU, within 3 months (wash-out allowed)
* Use of 1,25(OH)2D3 or an analogue, calcimimetics, or medications known to induce CYP24A1 within 4 weeks (wash-out allowed)
* Serum calcium \> 10.1 mg/dL
* Hemoglobin \< 10 g/dL

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No